A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates

Vaccine

Volumn 28, Issue 3, 2010, Pages 767-779

  Bartlett, Emmalene J ^a   Cruz, Ann Marie ^a   Boonyaratanakornkit, Jim ^a   Esker, Janice ^a   Castaño, Adam ^a   Skiadopoulos, Mario H ^a   Collins, Peter L ^a   Murphy, Brian R ^a   Schmidt, Alexander C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

C protein; Human parainfluenza virus; Vaccine candidates

Indexed keywords

INTERFERON; LIVE VACCINE; PARAINFLUENZA VACCINE; PROTEIN C; SPHINGOLIPID ACTIVATOR PROTEIN 2;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBODY TITER; APOPTOSIS; ARTICLE; CERCOPITHECIDAE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE DELETION; GENE MUTATION; IMMUNOGENICITY; NONHUMAN; OPEN READING FRAME; PARAINFLUENZA VIRUS 1; PARAINFLUENZA VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; APOPTOSIS; BASE SEQUENCE; CELL LINE; CERCOPITHECUS AETHIOPS; HUMANS; INTERFERON TYPE I; MOLECULAR SEQUENCE DATA; PARAINFLUENZA VACCINES; PARAINFLUENZA VIRUS 1, HUMAN; PHOSPHOPROTEINS; SEQUENCE DELETION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL LOAD; VIRAL PROTEINS; VIRULENCE; VIRUS REPLICATION;

EID: 71349086664     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.069     Document Type: Article

References (58)

1. Karron R.A., and Collins P.L. Parainfluenza viruses. In: Knipe D.M., and Howley P.M. (Eds). Fields virology. fifth ed. (2007), Lippincott Williams & Wilkins, Philadelphia 1497-1526 [Chapter 42]
2. Murphy B.R., Prince G.A., Collins P.L., Van Wyke Coelingh K., Olmsted R.A., Spriggs M.K., et al. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Res 11 1 (1988) 1-15
3. Iwane M.K., Edwards K.M., Szilagyi P.G., Walker F.J., Griffin M.R., Weinberg G.A., et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 113 June (6) (2004) 1758-1764
4. Marx A., Torok T.J., Holman R.C., Clarke M.J., and Anderson L.J. Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics. J Infect Dis 176 (1997) 1423-1427
5. Reed G., Jewett P.H., Thompson J., Tollefson S., and Wright P.F. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 years old. J Infect Dis 175 4 (1997) 807-813
6. Heikkinen T., Thint M., and Chonmaitree T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl J Med 340 4 (1999) 260-264
7. Counihan M.E., Shay D.K., Holman R.C., Lowther S.A., and Anderson L.J. Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States. Pediatr Infect Dis J 20 7 (2001) 646-653
8. Karron R.A., Makhene M., Gay K., Wilson M.H., Clements M.L., and Murphy B.R. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr Infect Dis J 15 8 (1996) 650-654
9. Karron R.A., Belshe R.B., Wright P.F., Thumar B., Burns B., Newman F., et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 22 May (5) (2003) 394-405
10. Belshe R.B., Newman F.K., Anderson E.L., Wright P.F., Karron R.A., Tollefson S., et al. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J Infect Dis 190 December 15 (12) (2004) 2096-2103
11. Greenberg D.P., Walker R.E., Lee M.S., Reisinger K.S., Ward J.I., Yogev R., et al. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. J Infect Dis 191 April 1 (7) (2005) 1116-1122
12. Bartlett E.J., Castano A., Surman S.R., Collins P.L., Skiadopoulos M.H., and Murphy B.R. Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes. Virol J 4 July 2 (1) (2007) 67
13. Nolan S.M., Skiadopoulos M.H., Bradley K., Kim O.S., Bier S., Amaro-Carambot E., et al. Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3′ genomic promoter mutation and l polymerase mutations are attenuated and protective in non-human primates. Vaccine 25 August 21 (34) (2007) 6409-6422
14. Slobod K.S., Shenep J.L., Lujan-Zilbermann J., Allison K., Brown B., Scroggs R.A., et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 22 August 13 (23-24) (2004) 3182-3186
15. McAuliffe J.M., Surman S.R., Newman J.T., Riggs J.M., Collins P.L., Murphy B.R., et al. Codon substitution mutations at two positions in the l polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro. J Virol 78 February (4) (2004) 2029-2036
16. Bartlett E.J., Amaro-Carambot E., Surman S.R., Collins P.L., Murphy B.R., and Skiadopoulos M.H. Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates. Vaccine 24 March 24 (14) (2006) 2674-2684
17. Newman J.T., Surman S.R., Riggs J.M., Hansen C.T., Collins P.L., Murphy B.R., et al. Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics. Virus Genes 24 1 (2002) 77-92
18. Itoh M., Isegawa Y., Hotta H., and Homma M. Isolation of an avirulent mutant of Sendai virus with two amino acid mutations from a highly virulent field strain through adaptation to LLC-MK2 cells. J Gen Virol 78 Pt 12 (1997) 3207-3215
19. Kurotani A., Kiyotani K., Kato A., Shioda T., Sakai Y., Mizumoto K., et al. Sendai virus C proteins are categorically nonessential gene products but silencing their expression severely impairs viral replication and pathogenesis. Genes Cells 3 2 (1998) 111-124
20. Latorre P., Cadd T., Itoh M., Curran J., and Kolakofsky D. The various Sendai virus C proteins are not functionally equivalent and exert both positive and negative effects on viral RNA accumulation during the course of infection. J Virol 72 7 (1998) 5984-5993
21. Bartlett E.J., Cruz A.M., Esker J., Castano A., Schomacker H., Surman S.R., et al. Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates. J Virol 82 September (18) (2008) 8965-8977
22. Garcin D., Marq J.B., Goodbourn S., and Kolakofsky D. The amino-terminal extensions of the longer Sendai virus C proteins modulate pY701-Stat1 and bulk Stat1 levels independently of interferon signaling. J Virol 77 February (4) (2003) 2321-2329
23. Gotoh B., Takeuchi K., Komatsu T., and Yokoo J. The STAT2 activation process is a crucial target of Sendai virus C protein for the blockade of alpha interferon signaling. J Virol 77 March (6) (2003) 3360-3370
24. Komatsu T., Takeuchi K., Yokoo J., and Gotoh B. C and V proteins of Sendai virus target signaling pathways leading to IRF-3 activation for the negative regulation of interferon-beta production. Virology 325 July 20 (1) (2004) 137-148
25. Bousse T., Chambers R.L., Scroggs R.A., Portner A., and Takimoto T. Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment. Virus Res 121 October (1) (2006) 23-32
26. Van Cleve W., Amaro-Carambot E., Surman S.R., Bekisz J., Collins P.L., Zoon K.C., et al. Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1. Virology 352 August 15 (1) (2006) 61-73
27. Curran J., Marq J.B., and Kolakofsky D. The Sendai virus nonstructural C proteins specifically inhibit viral mRNA synthesis. Virology 189 2 (1992) 647-656
28. Cadd T., Garcin D., Tapparel C., Itoh M., Homma M., Roux L., et al. The Sendai paramyxovirus accessory C proteins inhibit viral genome amplification in a promoter-specific fashion. J Virol 70 8 (1996) 5067-5074
29. Horikami S.M., Hector R.E., Smallwood S., and Moyer S.A. The Sendai virus C protein binds the l polymerase protein to inhibit viral RNA synthesis. Virology 235 2 (1997) 261-270
30. Tapparel C., Hausmann S., Pelet T., Curran J., Kolakofsky D., and Roux L. Inhibition of Sendai virus genome replication due to promoter-increased selectivity: a possible role for the accessory C proteins. J Virol 71 12 (1997) 9588-9599
31. Hasan M.K., Kato A., Muranaka M., Yamaguchi R., Sakai Y., Hatano I., et al. Versatility of the accessory C proteins of Sendai virus: contribution to virus assembly as an additional role. J Virol 74 12 (2000) 5619-5628
32. Sakaguchi T., Kato A., Sugahara F., Shimazu Y., Inoue M., Kiyotani K., et al. AIP1/Alix is a binding partner of Sendai virus C protein and facilitates virus budding. J Virol 79 July (14) (2005) 8933-8941
33. Irie T., Nagata N., Yoshida T., and Sakaguchi T. Recruitment of Alix/AIP1 to the plasma membrane by Sendai virus C protein facilitates budding of virus-like particles. Virology 371 February 5 (1) (2008) 108-120
34. Itoh M., Hotta H., and Homma M. Increased induction of apoptosis by a Sendai virus mutant is associated with attenuation of mouse pathogenicity. J Virol 72 4 (1998) 2927-2934
35. Heylbroeck C., Balachandran S., Servant M.J., DeLuca C., Barber G.N., Lin R., et al. The IRF-3 transcription factor mediates Sendai virus-induced apoptosis. J Virol 74 8 (2000) 3781-3792
36. Bitzer M., Armeanu S., Prinz F., Ungerechts G., Wybranietz W., Spiegel M., et al. Caspase-8 and Apaf-1-independent caspase-9 activation in Sendai virus-infected cells. J Biol Chem 277 August 16 (33) (2002) 29817-29824
37. Koyama A.H., Irie H., Kato A., Nagai Y., and Adachi A. Virus multiplication and induction of apoptosis by Sendai virus: role of the C proteins. Microbes Infect 5 April (5) (2003) 373-378
38. Peters K., Chattopadhyay S., and Sen G.C. IRF-3 activation by Sendai virus infection is required for cellular apoptosis and avoidance of persistence. J Virol 82 April (7) (2008) 3500-3508
39. Bartlett E.J., Amaro-Carambot E., Surman S.R., Newman J.T., Collins P.L., Murphy B.R., et al. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys. Vaccine 23 September 7 (38) (2005) 4631-4646
40. Newman J.T., Riggs J.M., Surman S.R., McAuliffe J.M., Mulaikal T.A., Collins P.L., et al. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses. J Virol 78 February (4) (2004) 2017-2028
41. Buchholz U.J., Finke S., and Conzelmann K.K. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 73 1 (1999) 251-259
42. Murphy B.R., Richman D.D., Chalhub E.G., Uhlendorf C.P., Baron S., and Chanock R.M. Failure of attenuated temperature-sensitive influenza A (H3N2) virus to induce heterologous interference in humans to parainfluenza type 1 virus. Infect Immun 12 1 (1975) 62-68
43. Stojdl D.F., Lichty B.D., tenOever B.R., Paterson J.M., Power A.T., Knowles S., et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4 October (4) (2003) 263-275
44. Tao T., Durbin A.P., Whitehead S.S., Davoodi F., Collins P.L., and Murphy B.R. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1. J Virol 72 4 (1998) 2955-2961
45. Komada H., Kusagawa S., Orvell C., Tsurudome M., Nishio M., Bando H., et al. Antigenic diversity of human parainfluenza virus type 1 isolates and their immunological relationship with Sendai virus revealed by using monoclonal antibodies. J Gen Virol 73 Pt 4 (1992) 875-884
46. Moeller K., Duffy I., Duprex P., Rima B., Beschorner R., Fauser S., et al. Recombinant measles viruses expressing altered hemagglutinin (H) genes: functional separation of mutations determining H antibody escape from neurovirulence. J Virol 75 16 (2001) 7612-7620
47. Kolakofsky D., Pelet T., Garcin D., Hausmann S., Curran J., and Roux L. Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J Virol 72 2 (1998) 891-899
48. Skiadopoulos M.H., Tatem J.M., Surman S.R., Mitcho Y., Wu S.L., Elkins W.R., et al. The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys. Vaccine 20 13 (2002) 1846-1852
49. Clements M.L., Belshe R.B., King J., Newman F., Westblom T.U., Tierney E.L., et al. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol 29 6 (1991) 1175-1182
50. Curran J., Pelet T., and Kolakofsky D. An acidic activation-like domain of the Sendai virus P protein is required for RNA synthesis and encapsidation. Virology 202 2 (1994) 875-884
51. Smallwood S., Ryan K.W., and Moyer S.A. Deletion analysis defines a carboxyl-proximal region of Sendai virus P protein that binds to the polymerase l protein. Virology 202 1 (1994) 154-163
52. Curran J., Marq J.B., and Kolakofsky D. An N-terminal domain of the Sendai paramyxovirus P protein acts as a chaperone for the NP protein during the nascent chain assembly step of genome replication. J Virol 69 2 (1995) 849-855
53. Ryan K.W., Murti K.G., and Portner A. Localization of P protein binding sites on the Sendai virus nucleocapsid. J Gen Virol 71 Pt 4 (1990) 997-1000
54. Kozak M. Initiation of translation in prokaryotes and eukaryotes. Gene 234 July 8 (2) (1999) 187-208
55. He B. Viruses, endoplasmic reticulum stress, and interferon responses. Cell Death Differ 13 March (3) (2006) 393-403
56. Medigeshi G.R., Lancaster A.M., Hirsch A.J., Briese T., Lipkin W.I., Defilippis V., et al. West Nile virus infection activates the unfolded protein response, leading to CHOP induction and apoptosis. J Virol 81 October (20) (2007) 10849-10860
57. Smith J.A., Turner M.J., DeLay M.L., Klenk E.I., Sowders D.P., and Colbert R.A. Endoplasmic reticulum stress and the unfolded protein response are linked to synergistic IFN-beta induction via X-box binding protein 1. Eur J Immunol 38 May (5) (2008) 1194-1203
58. Garcin D., Itoh M., and Kolakofsky D. A point mutation in the Sendai virus accessory C proteins attenuates virulence for mice, but not virus growth in cell culture. Virology 238 2 (1997) 424-431